Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block.
Amphastar Pharmaceuticals, Inc.
11570 6th Street., Rancho Cucamonga, CA 91730
CategoryBiotech & Pharmaceuticals
Amphastar’s environmental impact is intricately tied to its commitment to sustainable manufacturing and operational practices. Through responsible resource management, waste reduction, and energy-efficient processes, the company showcases its dedication to minimizing its ecological footprint. Amphastar’s efforts to minimize waste, optimize energy consumption, and adopt eco-friendly manufacturing practices reflect its commitment to environmental stewardship, contributing to a more sustainable future for the pharmaceutical industry.Amphastar’s social impact revolves around its mission to improve patient health and well-being. By developing high-quality generic and specialty pharmaceutical products, the company plays a pivotal role in enhancing patient access to essential medications. Additionally, Amphastar’s focus on affordability, patient education, and community engagement underscores its commitment to addressing healthcare disparities and fostering positive social change.Strong governance and ethical practices form the bedrock of Amphastar’s operations. The company adheres to rigorous standards of regulatory compliance, transparency, and ethical decision-making. Transparent communication about its products, manufacturing processes, and ethical considerations demonstrates Amphastar’s commitment to responsible governance, ensuring stakeholder trust and maintaining ethical standards.Amphastar’s financial sustainability is tightly intertwined with its strategic financial management practices. The company’s judicious allocation of resources to research and development, innovative solutions, and expansion initiatives ensures long-term value creation. By embracing strategic financial planning and fostering innovation, Amphastar maintains financial resilience while driving advancements in pharmaceutical solutions.Amphastar’s ethical responsibility extends to its pharmaceutical development practices. The company places patient safety, regulatory adherence, and ethical clinical trials at the forefront of its operations. By maintaining the highest standards of quality in its pharmaceutical products, Amphastar upholds ethical pharmaceutical practices that prioritize patient well-being and contribute to the overall integrity of the industry.